| Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells MCW Feltkamp, HL Smits, MPM Vierboom, RP Minnaar, BM De Jongh, ... European journal of immunology 23 (9), 2242-2249, 1993 | 1018 | 1993 |
| Identification of peptide sequences that potentially trigger HLA‐A2. 1‐restricted cytotoxic T lymphocytes HW Nijman, JGA Houbiers, MPM Vierboom, SH van der Burg, ... European journal of immunology 23 (6), 1215-1219, 1993 | 272 | 1993 |
| Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes MPM Vierboom, HW Nijman, R Offringa, EIH Voort, T Hall, L Broek, ... The Journal of experimental medicine 186 (5), 695-704, 1997 | 269 | 1997 |
| Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells. HW Nijman, MJ Kleijmeer, MA Ossevoort, VM Oorschot, MP Vierboom, ... The Journal of experimental medicine 182 (1), 163-174, 1995 | 258 | 1995 |
| Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques K Dijkman, CC Sombroek, RAW Vervenne, SO Hofman, C Boot, ... Nature medicine 25 (2), 255-262, 2019 | 247 | 2019 |
| Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16 … MLH De Bruijn, DH Schuurhuis, MPM Vierboom, H Vermeulen, ... Cancer Research 58 (4), 724-731, 1998 | 201 | 1998 |
| The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis M Van Roy, C Ververken, E Beirnaert, S Hoefman, J Kolkman, ... Arthritis research & therapy 17, 1-16, 2015 | 199 | 2015 |
| Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE* 3-Leiden transgenic mice BJM van Vlijmen, G Gerritsen, AL Franken, LSM Boesten, MM Kockx, ... Circulation research 88 (8), 780-786, 2001 | 199 | 2001 |
| Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumors MCW Feltkamp, GR Vreugdenhil, MPM Vierboom, E Ras, ... European journal of immunology 25 (9), 2638-2642, 1995 | 192 | 1995 |
| Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity MCW Feltkamp, MPM Vierboom, WM Kast, CJM Melief Molecular immunology 31 (18), 1391-1401, 1994 | 120 | 1994 |
| Inhibition of the development of collagen‐induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5 MPM Vierboom, PJ Zavodny, CC Chou, JR Tagat, C Pugliese‐Sivo, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2005 | 108 | 2005 |
| p53: a potential target antigen for immunotherapy of cancer R Offringa, MPM Vierboom, SH van der Burg, L Erdile, CJM Melief Annals of the New York Academy of Sciences 910 (1), 223-236, 2000 | 80 | 2000 |
| Antitumor Efficacy of Wild-Type p53-specific CD4+ T-Helper Cells S Zwaveling, MPM Vierboom, SC Ferreira Mota, JA Hendriks, ME Ooms, ... Cancer research 62 (21), 6187-6193, 2002 | 75 | 2002 |
| High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes MPM Vierboom, S Zwaveling, GMJ Bos, M Ooms, GM Krietemeijer, ... Cancer research 60 (19), 5508-5513, 2000 | 72 | 2000 |
| Preclinical models of arthritic disease in non-human primates MPM Vierboom, M Jonker, PP Tak, A Bert Drug discovery today 12 (7-8), 327-335, 2007 | 68 | 2007 |
| Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex … HW Nijman, JGA Houbiers, SH van der Burg, MPM Vierboom, ... Journal of immunotherapy 14 (2), 121-126, 1993 | 66 | 1993 |
| Modeling human arthritic diseases in nonhuman primates MPM Vierboom, M Jonker, RE Bontrop, B 't Hart Arthritis research & therapy 7, 1-10, 2005 | 65 | 2005 |
| Cyclophosphamide enhances anti‐tumor effect of wild‐type p53‐specific CTL MPM Vierboom, GMJ Bos, M Ooms, R Offringa, CJM Melief International journal of cancer 87 (2), 253-260, 2000 | 60 | 2000 |
| Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination MPM Vierboom, K Dijkman, CC Sombroek, SO Hofman, C Boot, ... Cell Reports Medicine 2 (1), 2021 | 58 | 2021 |
| Type II collagen antibody response is enriched in the synovial fluid of rheumatoid joints and directed to the same major epitopes as in collagen induced arthritis in primates … I Lindh, O Snir, E Lönnblom, H Uysal, I Andersson, KS Nandakumar, ... Arthritis research & therapy 16, 1-10, 2014 | 55 | 2014 |
